Patents by Inventor Kan Saiga

Kan Saiga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10945997
    Abstract: An object of the invention is to obtain a preparation which shows enhanced effectiveness and safety compared to tacrolimus, has the concentration in blood maintained at a constant level without individual differences, whereby the control of the amount of administration depending on the blood kinetics (blood trough concentration) becomes unnecessary. The present invention relates to a polymeric derivative of tacrolimus, in which a polyethylene glycol segment and an alcoholic hydroxy group of tacrolimus are bonded to side-chain carboxy groups of a polyaspartic acid derivative.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: March 16, 2021
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Nao Yoneki, Akihiro Sekiguchi, Kana Mizunuma, Yuki Kobayashi, Junpei Konno, Kan Saiga, Keiichirou Yamamoto
  • Publication number: 20200155518
    Abstract: An object of the invention is to obtain a preparation which shows enhanced effectiveness and safety compared to tacrolimus, has the concentration in blood maintained at a constant level without individual differences, whereby the control of the amount of administration depending on the blood kinetics (blood trough concentration) becomes unnecessary. The present invention relates to a polymeric derivative of tacrolimus, in which a polyethylene glycol segment and an alcoholic hydroxy group of tacrolimus are bonded to side-chain carboxy groups of a polyaspartic acid derivative.
    Type: Application
    Filed: December 19, 2016
    Publication date: May 21, 2020
    Inventors: Nao Yoneki, Akihiro Sekiguchi, Kana Mizunuma, Yuki Kobayashi, Junpei Konno, Kan Saiga, Keiichirou Yamamoto
  • Publication number: 20180334540
    Abstract: A problem of the present invention is to obtain a preparation which shows markedly enhanced effectiveness and safety by exhibiting high accumulability at diseased areas and having the blood concentration maintained at a constant level without individual differences, and for which the control of the dosage depending on the blood kinetics (blood trough concentration) becomes unnecessary. The invention relates to a polymeric derivative of tacrolimus including a copolymer of a polyethylene glycol segment and a polymeric moiety, in which a carboxy group in a side chain of the copolymer is bonded to an alcoholic hydroxy group of tacrolimus.
    Type: Application
    Filed: November 10, 2016
    Publication date: November 22, 2018
    Inventors: Akihiro Sekiguchi, Kana Mizunuma, Keiichirou Yamamoto, Nao Yoneki, Tomohiro Hayashi, Kan Saiga, Junpei Konno, Yuki Kobayashi, Takamichi Sato, Naoko Igo, Kimiko Fuchigami
  • Patent number: 9163080
    Abstract: A monoclonal antibody, wherein the monoclonal antibody specifically binds to a single-chain type IV collagen polypeptide, and wherein the monoclonal antibody is obtained by a hybridoma line of Anti NK-Antigen monoclonal antibody #141 having Accession No: FERM BP-11300.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: October 20, 2015
    Assignee: NIPPON KAYAKU KABUSHIKI KAISHA
    Inventors: Makoto Morita, Arihiro Tomura, Kan Saiga, Toshihiko Hayashi, Hidemitsu Sugihara, Kazuhiro Tokunaka, Takamichi Sato, Yasutada Imamura
  • Patent number: 7598244
    Abstract: Novel [1,2,4]triazolo[1,5-a]pyrimidine derivative of the general formula (1): (1) its prodrug or a pharmaceutically acceptable salt thereof, which exhibits an antigen presentation inhibiting activity and is useful as a preventive and/or therapeutic agent for immunological rejection and/or graft versus host reaction in organ/bone marrow transplant, autoimmune disease, allergic disease and/or inflammatory disease and also useful as an anticancer drug or as an immunological tolerance inducer for transplanted organ/transplanted bone marrow.
    Type: Grant
    Filed: June 2, 2004
    Date of Patent: October 6, 2009
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Akira Masuda, Yoshitaka Satoh, Yuji Akiyama, Kan Saiga, Eriko Toyoda
  • Publication number: 20070010515
    Abstract: Novel [1,2,4]triazolo[1,5-a]pyrimidine derivative of the general formula (1): (1) its prodrug or a pharmaceutically acceptable salt thereof, which exhibits an antigen presentation inhibiting activity and is useful as a preventive and/or therapeutic agent for immunological rejection and/or graft versus host reaction in organ/bone marrow transplant, autoimmune disease, allergic disease and/or inflammatory disease and also useful as an anticancer drug or as an immunological tolerance inducer for transplanted organ/transplanted bone marrow.
    Type: Application
    Filed: June 2, 2004
    Publication date: January 11, 2007
    Inventors: Akira Masuda, Yoshitaka Satoh, Yuji Akiyama, Kan Saiga, Eriko Toyoda
  • Patent number: 6210912
    Abstract: A method for detecting the onset of chronic rejection at an early stage after organ transplantation, characterized by assaying nitrogen trioxide (NO3), matrix metalloproteinase (MMP)-2 or the precursor thereof in body fluids drawn out of body.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: April 3, 2001
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Isamu Koyama, Tadaki Yasumura, Kyuichi Nemoto, Takako Mae, Kan Saiga, Hisako Takagi, Atsuko Isoda, Toshio Tanabe